Dr. Allyson Campbell Spence, MD, PhD

Dr. Spence practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Spence's NPI, 1023301074, was assigned on May 24, 2011. Dr. Spence graduated from Vanderbilt University School Of Medicine in 2000. Dr. Spence's California license number on file is A78809.

Dr. Spence's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Spence's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Spence to 1 more hospital, named with a free account. Dr. Spence's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spence practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Spence's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Spence is board certified in medical oncology by the American Board of Internal Medicine. Dr. Spence has a license on file in California.

Dmand AI lists breast cancer among the conditions Dr. Spence treats.

CMS data shows 101 Medicare services from Dr. Spence across 2 procedure codes in 2024, all of them office visits, for 50 Medicare patients. Medicare paid $6,178 for them.

CMS counts 50 Medicare patients who saw Dr. Spence in 2024. The largest group is 65 to 74, with 26 patients. 75% of them have cancer, and 60% have high blood pressure. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spence's median patient age at 59, with 93% women.

In 2024, Dr. Spence wrote 89 Medicare Part D claims for 27 patients. 84% of them were for generic drugs. CMS names the drug for 57 of them, across 1 drug with 11 or more claims each, at $1,306 in total drug cost. In 2023, CMS named 66 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Spence for performance year 2024, reported as part of a group. Dr. Spence accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spence as offering telehealth.

Dmand AI links 9 papers to Dr. Spence, published from 2015 to 2023. The most frequent topics are T-Lymphocytes, Regulatory, Cell Differentiation and Diabetes Mellitus, Type 1. Dr. Spence's most frequent co-authors are Thomas Floyd Osborne, MD, Susan Marie Swetter, MD and Mark S. Anderson, MD.

Dmand AI links Dr. Spence to 2 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, Follicular and Lymphoma, Non-Hodgkin. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 8 general payments to Dr. Spence from 6 drug and device companies from 2017 to 2024. Grants make up the largest share, 80% of the total. AstraZeneca Pharmaceuticals LP paid the most, $350.

Dr. Spence graduated from Vanderbilt University School Of Medicine in 2000.

Dr. Spence is in network with 6 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.